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Abstract
The present study was conducted in 30 patients of malignant pleural effusion and 30 patients of non malignant pleural 
effusion. Pleural fluid and blood samples were taken at the time of admission, before starting any treatment. Sialic acid levels 
were estimated in serum and pleural fluid by Warren’s TBA method. In the present study, serum sialic acid levels were higher 
in group II as compared to group I. In the present study, pleural fluid sialic acid levels and PF/S ratio was higher in malignant 
pleural effusion (though difference was not statistically significant). Smokers in group II had higher serum sialic acid as compared 
to group 1 (P<0.05).  The sensitivity and specificity of pleural fluid/serum sialic acid ratio with cut off value of 0.7 were 76.67% 
and 20% respectively, while taking the cut off value of 70 mg/dL for pleural fluid sialic acid in malignant pleural effusions, the 
sensitivity was 63.33%, specificity 60% and positive predictive value 46.34%. These findings indicate that determination of sialic 
acid levels in pleural fluid has diagnostic value as a cheap, simple and reliable marker for malignant pleural effusion.
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Introduction
Malignant disease involving pleura is the second leading cause 
of exudative pleural effusions after parapneumonic effusions. It is 
one of the most common diagnostic problems requiring detailed 
investigation, encountered by specialist
[1]. An increasing number 
of biochemical parameters have been reported to have diagnos-
tic value in malignant pleural effusions 
[2-4]. Sialic acid levels 
have been found to be elevated in neoplastic cells derived from 
lung, breast, stomach, and colon, and ovary, prostate and liver 
tumors
[5]. Recently sialic acid has been reported to have a diag-
nostic value
[4]. Hence, the present study is designed to measure 
sialic acid in pleural effusion and serum samples of patients in 
order to differentiate between malignant and nonmalignant 
diseases.
Materials and methods
The present study was conducted in sixty patients attend-
ing Outpatient Department of Tuberculosis and Respiratory 
Medicine in collaboration with Department of Biochemistry, 
Pt BDS PGIMS, Rohtak, India. They were subdivided into two 
groups of thirty patients each: Group I (patients with pleural 
effusion proved malignant by pleural biopsy) and Group II 
(controls with nonmalignant pleural effusion). Inclusion crite-
ria: sputum negative for AFB (at least on three occasions), con-
firmed malignant by pleural biopsy, exudative pleural effusion. 
All the cases were subjected to detailed clinical history, thor-
ough clinical examination and routine investigations. Pleural 
fluid and blood samples were taken at the time of admission, 
before starting any treatment. Sialic acid levels were estimated 
in serum and pleural fluid by Warren’s TBA method
[6]. Data so 
obtained was analyzed statistically; student’s t-test was applied 
and regression analysis was carried out.
Observations
The clinical characteristics of the two groups are given in 
Tab 1. In group I, there were 14 patients who were smokers, 
while in group II there were 21 smokers. In group I, 4 out of 
30 patients were cases of benign pleural effusion, 18 had tu-
bercular etiology, 10 had pneumonitis and 2 cases were with 
chylothorax. In group II, 5 had malignant effusion, 25 had lung 
cancer, and 1 had mediastinal neoplasia.
Pleural effusion and serum sialic acid levels were higher in 
group II as compared to group I, though the difference was not 
statistically significant (Tab 2). PF/S ratio was higher in group 
II as compared to group I though difference was not statistical-
ly significant. Also, smokers had high pleural fluid and serum 
sialic acid levels and PF/S ratio as compared to nonsmokers. 
Smoker in groups II had higher serum sialic acid as compared 
to group I (P<0.05).
Taking cut off value of pleural fluid sialic acid as 65 mg/dL, 
in malignant pleural effusion, sensitivity was 63.33%, specific-
ity 60% and positive predictive value 46.34% (Tab 3). Taking 
cut off value of 0.7 for PF/S sialic acid ratio, sensitivity was 
 中国肺癌杂志 
www.lungca.org·350· 中国肺癌杂志2010年4月第13卷第4期 Chin J Lung Cancer, April 2010, Vol.13, No.4
76.67%, specificity 20%, and positive predictive value 48.94% 
in malignant pleural effusion.
A positive correlation was observed between rise in sialic 
acid in pleural fluid and serum Sialic acid levels in group I (Fig1) 
and no significant correlation could be observed in group II.
 
Discussion
In the present study, serum sialic acid levels were higher 
in group II as compared to group I. Changes in sialic acid 
content of patient’s sera have been reported to reflect growth 
processes of benign and malignant character
[7]. Raised serum 
sialic acid levels have been reported in various cancers
[5]. Our 
findings are in agreement with those reported by Krolikowsky et 
al
[8]Bektemur et al
[9] have reported high serum sialic acid levels 
in malignant pleural effusions though difference was not statis-
tically significant. They also observed high pleural fluid sialic 
acid levels and PF/S ratio.
In the present study, pleural fluid sialic acid levels and PF/S 
ratio was higher in malignant pleural effusion (though differ-
ence was not statistically significant). Smokers in group II had 
Tab 1  Clinical characteristics
                                  Group I (n=30)  Group II (n=30)
Age                                           37.53                                 56.16
Sex                                        25M, 5F                             19M, 11F
Smokers (%)                   14 (46%)                              21 (70%)
Pleural fluid protein (g%)      4.01±0.83                             4.72±0.85
Group I: patients with pleural effusion proved malignant by pleural biopsy;
Group II: patients with nonmalignant pleural effusion.
Tab 2  Sialic acid levels in the two groups (Mean±SD, mg/dL) 
                                                                                                   Group I                                                                                                                          Group II
                                                        Smokers  Nonsmokers       Total                             Smokers                         Nonsmokers                     Total
Pleural fluid sialic acid                           64.40±24.01  67.21±22.24  65.99±22.62  79.15±20.03  72.97±15.52             77.29±18.75
Serum  sialic acid                                       73.76±21.87  80.04±18.43  77.14±20.03  81.73±21.95  90.20±13.48             84.75±20.12
Ratio                                                     0.87±0.21    0.82±0.12                            0.84±0.17            1.04±0.41                           0.80±0.19                 0.96±0.37
Tab 3  Discriminative value of sialic acid level and PF/S ratio in both 
              groups (%) 
                          Sensitivity      Specificity     Positive predictive value
Sialic acid >70 mg/dL      63.33               60.00          61.29
PF/S > 0.7          76.67              20.00          48.94
Fig 1  Correlation between PF and Serum Sialic acid in benign disease
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) higher serum sialic acid as compared to group I (P<0.05).
These findings are in agreement with those reported in 
literature
[8-11]. In the present study, the cases selected were of 
malignant pleural effusion in stage 4, so no correlation was 
done with stage of disease since our aim was to analyze sialic 
acid for differentiating malignant from nonmalignant pleural 
effusion.
In differential diagnosis of exudative pleural effusions, cy-
tology is the most sensitive method. Since cytology findings 
are positive in half of such fluids, combined use of reliable 
tumor marker and cytology is a logical approach. Elevated 
concentration of sialic acid could be due to implants of malig-
nant cells on pleura producing effusion as well as diffusion by 
pleural capillaries into pleural fluid.
On comparing sialic acid levels in serum and pleural fluid, 
33.33% of cases of malignant pleural effusions had raised 
pleural fluid sialic acid (>70 mg/dL) as compared to serum 
levels which were in the normal range. This could be either 
due to production and gradual absorption of sialic acid in dis-
eased area or elevation of both serum and pleural fluid levels, 
but sialic acid disappears more slowly from pleural fluid.
Reports comparing sialic acid levels in serum in various 
histopathological types have found raised levels in squamous 
cell carcinoma and small cell carcinoma
[12], but,  studies in 
pleural fluid are lacking. In the present study no specific cor-
relation of sialic acid with any particular histopathological 
type could be observed.
Smokers had higher pleural fluid sialic acid levels in ma-
lignant pleural effusion as compared to non smokers (Tab 2, 
P>0.05). While in benign pleural effusion pleural fluid  sialic 
acid levels were higher in non smokers (Tab 2, P>0.05). PF/S 
ratio was higher in smokers than in non smokers in malignant 
pleural effusion and lower in smokers in benign pleural effu-
sions (Tab 2, P<0.05, P>0.05, respectively).
Serum sialic acid levels have been reported to be increased 
PF: Pleural fluid; S: serum.
 中国肺癌杂志 
www.lungca.org·351· 中国肺癌杂志2010年4月第13卷第4期 Chin J Lung Cancer, April 2010, Vol.13, No.4
in smokers and alcoholics since smoking induces tissue inflam-
mation and is a known carcinogen
[13]. Hence elevated sialic 
acid levels in pleural fluid could be attributed to smoking and 
this could possibly a secondary process to malignancy that 
needs to be established by further studies. Since the studies 
have reported that total sialic acid levels remain unchanged fol-
lowing one year of smoking cessation
[13,14].
In the present study, a significant positive correlation was 
observed between pleural fluid and serum sialic serum sialic 
acid levels in benign pleural effusion (Fig 1). A positive corre-
lation was also observed between pleural fluid and serum sialic 
acid levels in malignant pleural effusion though difference was 
not statistically significant. Bektemur et al had also observed 
no significant correlation between pleural fluid to serum lipid 
bound sialic acid ratios in benign and malignant groups
[9].
Taking cut off value of 70 for pleural fluid sialic acid in ma-
lignant pleural effusions, sensitivity was 63.33%, specificity 
60% and positive predictive value 46.34% (Tab 3).
Taking cut off values of >0.7 for PF/S ratio, sensitivity was 
76.67%, specificity 20% and positive predictive value 48.94% 
(Tab 2). These findings are in agreement with those reported 
in literature
[10]. Thus, pleural fluid sialic acid in malignant pleu-
ral effusion along with PF/S ratio have good sensitivity and 
positive predictive value and can prove to be a reliable marker 
in differentiating benign and malignant pleural effusion.
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